Synergistic targeting of the ARID2-MYC axis by pomalidomide and panobinostat overcomes intrinsic IMiD resistance in multiple myeloma. - Yamamoto J; Asatsuma-Okumura T; Ito T; Iwai Y; Handa H; Yamaguchi Y (Scientific reports, 2026)